From registry study searches with comparator. Studies excluded (16) with reason
Appendix 10. Table of ECTRIMS abstracts
Reference (6 first authors) Study
type
Follow-up Relapse Disability Lesions Safety
Alemtuzumab (n=110)
A. Fält, S. Kågström, S. Safer Demirbüker, J. Hillert, P. Nilsson, C. Dahle, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs
x
Cladribine (n=2 434)
S. Schippling, M.P. Sormani, N. De Stefano, G. Giovannoni, A. Galazka, B.
Keller, et al. CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tab-lets or placebo. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
RCT 96 weeks
x
S. Cook, G. Giovannoni, T. Leist, S. Syed, A. Nolting, R. Schick. Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis. Multiple Sclerosis Journal 2018; 24: (S2) 328–529
2 years
x
Dimethyl fumarate (n=247 000)
K. Smoot, C. Chen, L. Lucas, T. Stuchiner, E. Lucassen, M. Romba, et al.
Providence Dimethyl Fumarate Registry: year five results on discontinuation and treatment outcomes. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs 5 years
x x
S. Urtiaga, M. Cerezo Garcia, V. Galán Sánchez-Seco, J. Sabin Muñoz, I.
Moreno Torres, M. Gómez Moreno, et al. Tolerability and safety of Dimethyl fumarate in relapsing multiple sclerosis: a prospective observational post-marketing study. Multiple Sclerosis Journal 2018; 24: (S2) 328–529
Obs
x
S. Safer Demirbüker, S. Kågström, A. Fält, A. Berglund, J. Hillert, P. Nilsson, et al. A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5). Multi-ple Sclerosis Journal 2018; 24: (S2) 530–737
Obs
x
J. Hanna, C. Prada, N. Everage, S. Kalari, P. Jayia, P. Singhal, et al. Patients treated with delayed-release dimethyl fumarate have no increased risk of her-pes zoster based on clinical trial and post-marketing report data. Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs
x
N.J. Everage, C.C. Jones, R. Das, J. Hanna, S. Liu, K. Balashov, et al. Safety and efficacy of delayed-release dimethyl fumarate in multiple sclerosis pa-tients treated in routine medical practice: interim analysis of ESTEEM. Multi-ple Sclerosis Journal 2018; 24: (S2) 530–737
Obs 5 years
x x
Fingolimod (n=6 460)
K. Bencsik, T. Biernacki, J. Füvesi, C. Rózsa, S. Komoly, P. Ács, et a. Interim data from the Hungarian Fingolimod Registry (CFTY720DHU01). Multiple Sclerosis Journal 2018; 24: (S2) 981–1026
Obs 3 years
x x
T. Ziemssen, H. Albrecht, J. Haas, L. Klotz, M. Lang, C. Lassek, et al. Treat-ment effectiveness in relapsing remitting multiple sclerosis patients treated for 5 years with fingolimod in clinical practice: interim results from the observa-tional study PANGAEA. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs 5 years
x x
T. Ziemssen, H. Albrecht, J. Haas, L. Klotz, M. Lang, C. Lassek, et al. Safety of fingolimod in RRMS patients treated for up to 5 years in real world: interim results from the non-interventional PANGAEA study. Multiple Sclerosis Jour-nal 2018; 24: (S2) 121–327
Obs 5 years
x
A. Fält, S. Kågström, S. Safer Demirbüker, J. Hillert, P. Nilsson, C. Dahle, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2). Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs
x x x
C. Lebrun-Frenay, C. Papeix, G. Kobelt, J.M. Visy, M. Coustans, M. Debou-verie, et al. Long-term efficacy, safety and tolerability with fingolimod treat-ment in patients with multiple sclerosis in real-world settings in France: three-year results of the VIRGILE study. Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs 3 years
x x x
L. Moiola, F. Esposito, M. Di Cristinzi, L. Ferre’, G. Sferruzza, M. Romeo, et al. Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients. Multiple Sclerosis Journal 2018; 24: (S2) 8–120
Obs
x x x
J. Lorscheider, S. Schädelin, P. Benkert, C. Lienert, P. Hänni, T. Derfuss, et al. Early versus delayed initiation of fingolimod or dimethyl fumarate in relaps-ing-remitting multiple sclerosis. Multiple Sclerosis Journal 2018; 24: (S2) 121–
327
Obs 1,2 years
x
M. Guger, C. Enzinger, F. Leutmezer, J. Kraus, S. Kalcher, E. Kvas, et al. Ef-fects of real life use of oral disease-modifying treatments for relapsing-remit-ting multiple sclerosis in Austria over one year. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs 12 months
x x
Glatiramer acetate (2 758)
O. Fernandez, A. Rodriguez-Antiguedad, R. Cadima, I. Botella. Spanish reg-istry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment:
real-world results and initial results of first year follow-up. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs 5 years
x x x x
G. Giovannoni, P. Brex, E. Walters, S. Al-Izki, D. Dhiraj, K. Schmierer. Glati-ramer acetate slows disability progression - final 10-year results from UK Risk Sharing Scheme. Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs 10 years
x
T. Scott, O. Mokliatchouck, C. Castrillo-Viguera, A. Harrington, M.L. Naylor.
Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: propensity score matching of phase 3 data from ADVANCE and CONFIRM. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
RCT 2 years
x x
Natalizumab (186 777)
G. Giovannoni, L. Kappos, J. Berger, G. Cutter, R.J. Fox, H. Wiendl, et al. In-cidence of natalizumab-associated progressive multifocal leucoencephalopa-thy and its relationship with the pattern of natalizumab exposure over time.
Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs
x
N. Schwab, T. Schneider-Hohendorf, I. Meinl, S. Windhagen, L. Klotz, C.
Gross, et al. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of JCV ab index surveillance. Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs
x
A. Manouchehrinia, K. McKay, S. Kågström, A. Berglund, J. Lycke, F. Piehl, et al. Long-term effectiveness of natalizumab in multiple sclerosis: a 10-year nationwide prospective cohort study. Multiple Sclerosis Journal 2018; 24: (S2) 328–529
Obs 10 years
x
S. Kågström, A. Fält, S. Safer Demirbüker, A. Berglund, J. Hillert, P. Nilsson, et al. A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1). Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs
x
Rituximab (n=10 952)
B. Evertsson, K. Fink, A. Finn, F. Piehl, F. Nimer. Low dose rituximab de-pletes B cells and lowers IgM in blood in MS patients: a study on possible bi-omarkers to predict treatment response and adverse event profile. Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs 7 months
G. Luna, F. Piehl, T. Frisell. Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and in-jectable therapies: a nationwide cohort study. Multiple Sclerosis Journal 2018;
24: (S2) 328–529
Obs
x
E. Alvarez, K. Nair, I. Shelton, N. Zanganeh, S. Sillau, J. Corboy, et al. Evalu-ating the tolerability and safety profile of switching from rituximab to ocreli-zumab: infusion related reactions in relapsing forms of multiple sclerosis. Mul-tiple Sclerosis Journal 2018; 24: (S2) 530–737
x
Teriflunomide (n=7 247)
R. Zivadinov, M.G. Dwyer, E. Carl, K. Thangavelu, S. Cavalier, N. Bergsland.
Evaluating the effect of teriflunomide on whole brain atrophy in the phase 3 TOPIC study. Multiple Sclerosis Journal 2018; 24: (S2) 328–529
RCT 24 months
x
M. Magyari, M. Buron, Z. Illes, F. Sellebjerg. The Danish experience of teri-flunomide treatment in relapsing remitting multiple sclerosis. Multiple Sclero-sis Journal 2018; 24: (S2) 328–529
Obs 2 years
x
127 Appendices – Study selection
J. Villafani, J. Peña, V. Gonzalez-Quintanilla, P. Oliva, R. Suarez, D.M. Solar, et al. High persistence rate and sustained efficacy of teriflunomide in relaps-ing-remitting multiple sclerosis in real-world practice: a 3-year retrospective, multicenter study. Multiple Sclerosis Journal 2018; 24: (S2) 530–737
Obs 3 years
x x x x
S. Safer Demirbüker, S. Kågström, A. Fält, J. Hillert, P. Nilsson, C. Dahle, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4). Multiple Sclerosis Journal 2018; 24: (S2) 121–327
Obs 2 years
x x
D.A. Laplaud, L. Barbin, R. Casey, M. Debouverie, S. Vukusic, P. Labauge, et al. Comparative efficacy of teriflunomide versus dimethyl-fumarate on clinical and MRI outcomes: a two years French multicenter observational study. Mul-tiple Sclerosis Journal 2018; 24: (S2) 8–120
Obs 2 years
x x x
M. Buron, M. Magyari, T. Ameri Chalmer, H. Hassanpour-Kalam-Roudy, Z. Il-lés, Z. Mezei, et al . Comparative effectiveness of teriflunomide and dimethyl fumarate in relapsing remitting multiple sclerosis. A Danish nationwide cohort study. Multiple Sclerosis Journal 2018; 24: (S2) 8–120
Obs 2 years
x x x
Obs, Observational study; RCT, randomised controlled trial